BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 3, 2007
View Archived Issues
Fate Tempts VCs With Viable Stem Cell Business Model
Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)
Read More
Panel: FDA's Science 'Weak'; Increased Funding Needed
Read More
New Discoveries May Aid HIV Prevention, Treatment
Read More
FDA Amendments Act - Detrimental To Advertising Prescription Drug
Read More
Financings Roundup
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Appointments And Advancements
Read More